Table 1 |
||||||||
|
Demographic and clinical information of 29 samples used for mRNA/miRNA profiling |
||||||||
|
Sample ID |
Group |
FVC % |
Gender |
Age |
Race |
Cigarette smoking |
Clinical diagnosis |
RNA profiling |
|
|
||||||||
|
4 |
1 |
< 50% |
Male |
37 |
Caucasian |
Unknown |
UIP/IPF |
mRNA/miRNA |
|
6 |
1 |
< 50% |
Female |
45 |
African-American |
Never |
UIP/IPF |
mRNA/miRNA |
|
7 |
1 |
< 50% |
Female |
26 |
Caucasian |
Never |
FU |
mRNA/miRNA |
|
9 |
1 |
< 50% |
Male |
64 |
Caucasian |
Previous |
UIP/IPF |
mRNA |
|
10 |
1 |
< 50% |
Female |
58 |
Caucasian |
Never |
UIP/IPF |
mRNA/miRNA |
|
11 |
2 |
50~80% |
Male |
58 |
Caucasian |
Unknown |
UIP/IPF |
mRNA/miRNA |
|
12 |
2 |
50~80% |
Female |
66 |
Caucasian |
Never |
NSIP |
mRNA |
|
13 |
2 |
50~80% |
Male |
57 |
Caucasian |
Previous |
NSIP |
mRNA/miRNA |
|
14 |
2 |
50~80% |
Male |
60 |
Caucasian |
Unknown |
UIP/IPF |
mRNA/miRNA |
|
16 |
2 |
50~80% |
Male |
61 |
Caucasian |
Previous |
UIP/IPF |
mRNA/miRNA |
|
17 |
2 |
50~80% |
Female |
69 |
Caucasian |
Never |
HP |
mRNA/miRNA |
|
19 |
2 |
50~80% |
Male |
68 |
Caucasian |
Previous |
UIP/IPF |
mRNA/miRNA |
|
20 |
2 |
50~80% |
Male |
80 |
Caucasian |
Previous |
NSIP |
mRNA |
|
21 |
3 |
> 80% |
Male |
65 |
Caucasian |
Previous |
NSIP |
mRNA/miRNA |
|
22 |
3 |
> 80% |
Male |
52 |
Hispanic |
Never |
RB-ILD |
mRNA/miRNA |
|
23 |
3 |
> 80% |
Male |
39 |
Caucasian |
Previous |
RB-ILD |
mRNA/miRNA |
|
24 |
3 |
> 80% |
Male |
61 |
Caucasian |
Previous |
COP |
mRNA/miRNA |
|
25 |
3 |
> 80% |
Female |
68 |
Caucasian |
Never |
UIP/IPF |
mRNA |
|
26 |
3 |
> 80% |
Male |
53 |
Caucasian |
Never |
COP |
mRNA/miRNA |
|
27 |
3 |
> 80% |
Female |
50 |
African-American |
Previous |
NSIP |
mRNA/miRNA |
|
28 |
3 |
> 80% |
Female |
66 |
Caucasian |
Previous |
HP |
mRNA/miRNA |
|
29 |
3 |
> 80% |
Male |
64 |
Caucasian |
Previous |
UIP/IPF |
mRNA/miRNA |
|
30 |
3 |
> 80% |
Male |
56 |
Caucasian |
Previous |
UIP/IPF |
mRNA/miRNA |
|
43 |
Normal |
- |
Female |
71 |
Caucasian |
Unknown |
Uninvolved carcinoma tissue |
mRNA/miRNA |
|
44 |
Normal |
- |
Female |
81 |
Caucasian |
Unknown |
Uninvolved carcinoma tissue |
mRNA/miRNA |
|
46 |
Normal |
- |
Male |
50 |
Caucasian |
Unknown |
Uninvolved carcinoma tissue |
mRNA/miRNA |
|
48 |
Normal |
- |
Male |
73 |
Caucasian |
Unknown |
Uninvolved carcinoma tissue |
mRNA/miRNA |
|
50 |
Normal |
- |
Female |
73 |
Caucasian |
Unknown |
Uninvolved carcinoma tissue |
mRNA/miRNA |
|
51 |
Normal |
- |
Male |
29 |
Unknown |
Previous |
Lung transplant patient |
mRNA/miRNA |
|
|
||||||||
|
Abbreviation : FVC (forced vital capacity), UIP/IPF (usual interstitial pneumonitis/idiopathic pulmonary fibrosis), NSIP (non-specific interstitial pneumonitis), HP (hypersensitive pneumonitis), COP (cryptogenic organizing pneumonia), RB-ILD (respiratory bronchiolitis-interstitial lung disease) |
||||||||
|
Cho et al. BMC Medical Genomics 2011 4:8 doi:10.1186/1755-8794-4-8 |
||||||||
